ProMIS Neurosciences Inc.

0.57
-0.02 (-3.13%)
At close: Apr 28, 2025, 12:58 PM
-3.13%
Bid 0.57
Market Cap 18.59M
Revenue (ttm) n/a
Net Income (ttm) 2.78M
EPS (ttm) 0.11
PE Ratio (ttm) 5.17
Forward PE -1.48
Analyst Buy
Ask 0.59
Volume 22,330
Avg. Volume (20D) 37,278
Open 0.61
Previous Close 0.59
Day's Range 0.56 - 0.62
52-Week Range 0.51 - 2.37
Beta 0.29

About PMN

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded protei...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 10, 2007
Employees 7
Stock Exchange NASDAQ
Ticker Symbol PMN
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for PMN stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 954.85% from the latest price.

Stock Forecasts
5 months ago
+5.83%
ProMIS Neurosciences shares are trading higher aft... Unlock content with Pro Subscription
9 months ago
-17.47%
ProMIS Neurosciences shares are trading lower. The company presented preclinical data at the 2024 Alzheimer's Association International Conference.